Ge Long Hui A P P·2026-01-12 08:45Core Viewpoint - WuXi AppTec (603259.SH) expects significant revenue and profit growth for the fiscal year 2025, driven by its integrated CRDMO business model and increasing client demand for enabling services [1] Financial Performance - The company anticipates a revenue of approximately RMB 45.456 billion, representing a year-on-year increase of about 15.84% [1] - Adjusted net profit attributable to shareholders is expected to be around RMB 14.957 billion, reflecting a year-on-year growth of approximately 41.33% [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be about RMB 13.241 billion, with a year-on-year increase of approximately 32.56%, primarily impacted by exchange rate fluctuations [1] - Total net profit is expected to reach approximately RMB 19.151 billion, marking a year-on-year growth of about 102.65% [1] - The total profit for the period is projected to be around RMB 23.906 billion, indicating a year-on-year increase of approximately 107.16% [1] - Basic earnings per share are expected to be around RMB 6.70, reflecting a year-on-year growth of approximately 104.27% [1] Business Strategy - The company continues to focus on its unique "integrated, end-to-end" CRDMO business model, aiming to meet the growing client demand for enabling services [1] - WuXi AppTec is committed to expanding new capabilities, building new production capacity, and continuously optimizing production processes to enhance operational efficiency [1] - The company aims to drive steady business growth while efficiently empowering clients and striving to deliver more new and effective drugs to global patients [1]